SFI
NAVB

Susquehanna Fundamental Investments’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-32,822
Closed -$71K – 1685
2020
Q4 		$71K Sell
32,822
-18,826
-36% -$44.4K ﹤0.01% 1439
2020
Q3 		$139K Buy
51,648
+33,548
+185% +$120K ﹤0.01% 1247
2020
Q2 		$71K Buy
+18,100
New +$34.6K ﹤0.01% 927

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna Fundamental Investments's NAVB Position: Q1 2021 in Review

Susquehanna Fundamental Investments sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2021, closing a stake of 32,822 shares — an estimated $71K sold.

Susquehanna Fundamental Investments first reported a position in NAVB in Q2 2020 and held it in 3 quarters. The position peaked at $139K in Q3 2020. 35 funds tracked by Wall St. Rank hold NAVB as of Q1 2021.

  • Susquehanna Fundamental Investments reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 32,822 Navidea Biopharmaceuticals Inc. shares in Q1 2021, an estimated $71K.
  • Susquehanna Fundamental Investments first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2020 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Navidea Biopharmaceuticals Inc. position peaked at $139K in Q3 2020.
  • 35 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2021, filed 17 May 2021.